首页> 外文OA文献 >Faculty Opinions recommendation of First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

【2h】

Faculty Opinions recommendation of First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

机译：教师意见提出先进的抗CD47抗体HU5F9-G4的先进，先进的阶段I阶段试验。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sekhar Reddy;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers [J] . Sikic Branimir I, Lakhani Nehal, Patnaik Amita, Journal of Clinical Oncology . 2019,第12期

机译：先进的癌症患者抗CD47抗体HU5F9-G4的先进，先进的一类阶段I.
2. 295?First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas [J] . Nehal Lakhani, Marlana Orloff, Siqing Fu, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：295？IBI188的第一阶段I试验IBI188，靶向单克隆抗体的抗CD47，患有先进的实体瘤和淋巴瘤的患者
3. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors [J] . Hidalgo Manuel, Martinez-Garcia Maria, Le Tourneau Christophe, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第7期

机译：第一阶段I研究单药剂凡源蛋白，一流的双特异性抗血管发射素-2 /抗VEGF-A抗体，在成年患者晚期实体肿瘤
4. Comparison of Bridge and ACE-Format Assays for Anti-Drug Antibodies in Anti-IL-17A Treated Healthy Donors from Phase I Clinical Trial [C] . Tatyana Ostroukhova, Olesya Bulaeva, Evgenia Gerasimovich, Protein Engineering Summit. . 2018

机译：抗药物抗药抗体的桥梁和ACE格式测定从I临床试验中治疗的健康供体中的抗药物抗体测定
5. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
6. First-in-Human First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers [O] . Branimir I. Sikic, Nehal Lakhani, Amita Patnaik, -1

机译：抗CD47抗体Hu5F9-G4在晚期癌症患者中的首次人类首次一流I期试验
7. Faculty Opinions recommendation of Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. [O] . Sherene Loi 2019

机译：局部晚期或转移性乳腺癌患者Avelumab，抗PD-L1抗体的教师意见推荐：1B标枪实体瘤研究。

Faculty Opinions recommendation of First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

著录项

相似文献

相关主题

期刊订阅